Trial reportBMC pulmonary medicine2009
Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report.
Trial report in BMC pulmonary medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 4 syntheses or guidelines pooled it, 169 citations in OpenAlex.
- The meta-analysis for ideal cytokines to distinguish the latent and active TB infection.BMC pulmonary medicine · 2020Pooled it
- Gaps in Study Design for Immune Parameter Research for Latent Tuberculosis Infection: A Systematic Review.Journal of immunology research · 2020Pooled it
- Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis.Scientific reports · 2019Pooled it
- Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis.The Journal of infectious diseases · 2011Pooled it
- Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis.Frontiers in immunology · 2019Trial
- Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.PLoS pathogens · 2017Trial
- Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort.PloS one · 2010Trial
- IL-5 and IP-10 Detected in Quantiferon Supernatants Distinguish Latent Tuberculosis from Healthy Individuals in Areas with High Burden in Lima, Peru.Pathogens (Basel, Switzerland) · 2025Article
- The pivotal role of immune functional assays in deciphering immune function alterations.Clinical and experimental immunology · 2025Article
- Multiplexed cytokine profiling identifies diagnostic signatures for latent tuberculosis and reactivation risk stratification.PloS one · 2025Article
- Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis.The Journal of infection · 2024Article
- Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection.Nature communications · 2024Article
- Field evaluation of a point-of-care triage test for active tuberculosis (TriageTB).BMC infectious diseases · 2023Observational
- Mycobacterium tuberculosis-specific cytokine responses according to HIV status among household contacts of people with TB.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection.Tropical medicine and infectious disease · 2023Review
- Cytokine/chemokine profiles in people with recent infection byFrontiers in immunology · 2023Article
- Evidence, Challenges, and Knowledge Gaps Regarding Latent Tuberculosis in Animals.Microorganisms · 2022Review
- Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis?Frontiers in immunology · 2022Article
- Review of investigational medical devices' clinical trials and regulations in Africa as a benchmark for new innovations.Frontiers in medical technology · 2022Review
- Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterferon gamma release assays, including the QuantiFERON TB Gold In Tube (QFT) have been shown to be accurate in diagnosing Mycobacterium tuberculosis infection. These assays however, do not discriminate between latent TB infection (LTBI) and active TB disease.
methodsWe recruited twenty-three pulmonary TB patients and 34 household contacts from Cape Town, South Africa and performed the QFT test. To investigate the ability of new host markers to differentiate between LTBI and active TB, levels of 29 biomarkers in QFT supernatants were evaluated using a Luminex multiplex cytokine assay.
resultsEight out of 29 biomarkers distinguished active TB from LTBI in a pilot study. Baseline levels of epidermal growth factor (EGF) soluble CD40 ligand (sCD40L), antigen stimulated levels of EGF, and the background corrected antigen stimulated levels of EGF and macrophage inflammatory protein (MIP)-1beta were the most informative single markers for differentiation between TB disease and LTBI, with AUCs of 0.88, 0.84, 0.87, 0.90 and 0.79 respectively. The combination of EGF and MIP-1beta predicted 96% of active TB cases and 92% of LTBIs. Combinations between EGF, sCD40L, VEGF, TGF-alpha and IL-1alpha also showed potential to differentiate between TB infection states. EGF, VEGF, TGF-alpha and sCD40L levels were higher in TB patients.
conclusionThese preliminary data suggest that active TB may be accurately differentiated from LTBI utilizing adaptations of the commercial QFT test that includes measurement of EGF, sCD40L, MIP-1beta, VEGF, TGF-alpha or IL-1alpha in supernatants from QFT assays. This approach holds promise for development as a rapid diagnostic test for active TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.